NewAmsterdam Q2 2026: $678M Cash, Pipeline Catalysts Lined Up
NAMS sits 30% above its 52-week low of $21.234.
Summary
NewAmsterdam Pharma posted a $64.1M net loss for Q2 2026 and held $678.3M in cash, while highlighting key upcoming milestones including the PREVAIL interim analysis and RUBENS topline data.
Key Events · Earnings and Guidance · NAMS
-
Q2 2026 Financial Results
Revenue came in at $3.7M against a net loss of $64.1M, as R&D expenses climbed 51% to $41.7M, reflecting the ramp-up in clinical trial activity.
-
Strong Cash Position
Cash, equivalents, and marketable securities stood at $678.3M on June 30, 2026, down from $728.9M at year-end 2025, providing ample runway through key catalysts.
-
PREVAIL Interim Analysis Timeline
An interim analysis of the cardiovascular outcomes trial is planned for 4Q2026, with results expected in 1Q2027 — a major binary event for the stock.
-
RUBENS Phase 3 Topline Data by Year-End
The 300-patient trial in type 2 diabetes and metabolic syndrome remains on track to report topline data by the end of 2026.
Analysis · NAMS · Life Sciences
A 51% surge in R&D spending to $41.7M drove NewAmsterdam's Q2 2026 net loss to $64.1M, as the company pushes forward with obicetrapib trials. With $678.3M in cash, the runway comfortably extends through a series of upcoming catalysts: an interim analysis of the PREVAIL cardiovascular outcomes trial in 4Q2026 (results due 1Q2027), topline data from the RUBENS Phase 3 study by year-end, and the launch of a new Alzheimer's trial this year. The CHMP positive opinion in July already set a favorable regulatory tone; today's update adds the financial picture and a sharper timeline for the data readouts that could shape the stock's trajectory.
At the time of this filing, NAMS was trading at $27.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $21.23 to $42.21. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.